Thibault Mesplède

Assistant Professor

Erasmus MC

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thibault Mesplède is an Assistant Professor at Erasmus MC in the Netherlands. His research focuses on HIV treatment and resistance, including the optimization of long-acting therapies and the investigation of integrase inhibitors. He has contributed to recent publications examining dolutegravir resistance and unique controller phenotypes in HIV-2 cohorts.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Peter Katsikis

Professor & Head

Erasmus University Medical Center

NETHERLANDS

View details

Juan Carlos Zapata

University of Maryland School of Medicine

UNITED STATES

View details

Yvonne Mueller

Assistant Professor

Erasmus University Medical Center

NETHERLANDS

View details

Mekayla Forrest

McGill University

CANADA

View details

David van de Vijver

Erasmus University Rotterdam

NETHERLANDS

View details

Casper Rokx

Erasmus University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thibault Mesplède

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Insights to a Cure: Unique Controller Phenotypes in the Rotterdam HIV-2 Cohort

How frequent is dolutegravir resistance?

Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions

Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations

HIV-1 Integrase T218I/S Polymorphisms Do Not Reduce HIV-1 Integrase Inhibitors’ Phenotypic Susceptibility

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Investigational drugs for HIV: trends, opportunities and key players

Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence

Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir

Early Antiretroviral Therapy Prevents Viral Infection of Monocytes and Inflammation in Simian Immunodeficiency Virus-Infected Rhesus Macaques

Lamivudine-resistant HIVM184V is Durably Suppressed with Dolutegravir plus Lamivudine Dual Therapy in Humanized Mice

Collaborators (6)

Peter Katsikis

Juan Carlos Zapata

Yvonne Mueller

Mekayla Forrest

David van de Vijver

Casper Rokx

Make your next move.